Madame Bioscience Public Company Limited Receivables

The latest receivables for GLOCON.BK is $170M as of June 2026. That compares with $220M in the prior-year period — down 22.5% year over year. Investors often review this figure alongside Madame Bioscience Public Company Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, GLOCON.BK's receivables moved from $220M to $170M — a 22.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Madame Bioscience Public Company Limited's operating scale or balance-sheet position.

A receivables figure of $170M for GLOCON.BK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GLOCON.BK's receivables ($170M), review year-over-year change from $220M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.